Hyperglycemia Management – Medication Therapy

Slides:



Advertisements
Similar presentations
Oral Hypoglycemic Drugs And Classifications
Advertisements

Implementing Diabetes Guidelines in the “Real World” Martin J. Abrahamson, MD FACP Associate Professor of Medicine, Harvard Medical School Senior Vice.
Oral Medications to Treat Type 2 Diabetes
ADVANCE IN TREATMENT OF TYPE 2 D.M. BY DR : RAMYAHMED SAMY M.D. LECTURER OF INTERNAL MEDICINE BANHA UNIVERSITY
Barriers to Diabetes Control Mark E. Molitch, MD.
Diabetes Treatments: Options for Insulin Delivery Bonnie Pepon, RN, BSN, CDE Certified Diabetes Educator Conemaugh Diabetes Institute.
DIABETES MELLLITUS Strategies for Achieving Control in an Office Setting.
Criteria for the diagnosis of DM Symptoms of diabetes plus random blood glucose concentration ≥ 200 mg/dl OR FPG ≥ 126 mg/dl OR Two –hour plasma glucose.
Oral Hypoglycemic Drugs
Clinical Diabetes basic training
DRUGHYPOGLYCE MIA RISK ~A1C REDUCTI ON WEIGH T CHANG E ADVANTAGESDISADVANTAGES/ SIDE EFFECTS METFOR MIN No1.0 – 2.0%LOSSDecreased CV events and mortality;
Managing Type 2 Diabetes: Review of Recent Guidelines Gina Ryan, Pharm.D., BCPS, CDE Clinical Associate Professor Mercer University College of Pharmacy.
Treatment Advances in Type 2 Diabetes Panhandle Nurse Practitioner Symposium April 11, 2015 Dr. Caleb Kim.
Diabetes – New Guidelines and Treatments
The Role of DPP-IV Inhibitors in the Management of Type 2 Diabetes
TYPE 2 DIABETES MELLITUS Cynthia Brown, MN, ANP, CDE.
Type 2 diabetes treatment: Old and New Emily Szmuilowicz, MD, MS Assistant Professor of Medicine Division of Endocrinology Northwestern University.
Diabetes Crash Course: The Outpatient Setting Dr. Andrew Schmelz, PharmD Post-Doctoral Teaching Fellow Purdue University October 7, 2008
New Diabetes Therapies: Practical Considerations for Outpatient Use Sarah L. Anderson, PharmD, BCPS CPS 2016 Winter Seminar January 13, 2016.
Oral hypoglycemic drugs
Diabetes Board Review March 5, 2016 Jon McKrell, MD Heritage Valley FM Residency Program.
KATE VELTMAN Drug use changes after Whipple pancreaticduodenectomy.
1 ‘Medicines used in the management of Type 2 Diabetes’ Dr Susan McGeoch, Specialist Registrar in Diabetes Sandra Wilson, Diabetes Specialist Nurse.
Journal Club 9/15/11 Sanaz Sakiani, MD 1 st Year Endocrine Fellow Combining Basal Insulin Analogs with Glucagon-Like Peptide-1 Mimetics.
Diabetes mellitus. Fasting venous plasma glucose ≥ 7mmol/l(126mg/dl) Metabolic disorder, hyperglycemia, abnormality in C.H,fat, protein metabolism. Defect.
Dr. Mansour Alzahrani. متى اكتشف داء السكري؟ داء السكري في الحضارة الهندية والصينية القديمة اسهامات علماء المسلمين في داء السكري.
BOOK OF POTIONS UPDATE ON TYPE 2 DIABETES MEDICATIONS CHRISTINE SUCHAN, APRN APRIL 29, 2016.
Oral hypoGLYCEMICS.
Dr. Sasan Zaeri (PharmD, PhD) Department of Pharmacology, BPUMS.
DIABETES Shantana Jones Clinical Seminar II. Prevalence  25.8 million children and adults have diabetes  Diagnosed: 18.8 million people  Undiagnosed:
Medications Used in the Treatment of Diabetes Mellitus
Updates in Insulin Therapy
Copyright © 2015 by the American Osteopathic Association.
Gail Bradley MD Community Paramedicine Consortium - West
Stephen N. Davis, MBBS, FRCP, MACP
Objectives Review factors for best therapeutic approach for appropriate pharmacologic choices for diabetes management Review cost implications for.
Shared Decision Making and the Medical Treatment of Type 2 Diabetes
James Thrasher, MD  The American Journal of Medicine 
Antihyperglycemic Agents and Renal Function
Dr. Sasan Zaeri (PharmD, PhD) Department of Pharmacology, BPUMS
Diabetes Medication Update: Beyond A1c
6.Fat- increased lipolysis, inc FFA
Hi, folks.
Therapeutics Tutoring
Diabetes mellitus Prof. Dr. Borvendég János.
Diabetes Medications in the Top 200
What’s New in Type 2 Diabetes? 2018 Diabetes Updates
Rachel Naida, PharmD, CDE Clinical associate professor
Diabetes 101: Myths and Facts
Diabetes Update NP Conference April 16, 2015
Chapter 13 (Updated November 2016)
Diabetes Jessica Tagerman PharmD
Pharmacology Autumn Steen, PharmD, BCACP, CDE, CPP
Antihyperglycemic therapy in type 2 diabetes: general recommendations.
Diabetes.
Options for Combination Therapy in Type 2 Diabetes: Comparison of the ADA/EASD Position Statement and AACE/ACE Algorithm  Timothy Bailey, MD  The American.
James Thrasher, MD  The American Journal of Medicine 
Antihyperglycemic therapy in type 2 diabetes: general recommendations (17). Antihyperglycemic therapy in type 2 diabetes: general recommendations (17).
Antihyperglycemic therapy in type 2 diabetes: general recommendations.
Antihyperglycemic therapy in type 2 diabetes: general recommendations.
Approach to starting and adjusting insulin in type 2 diabetes.
DM management Dr.Duaa Hiasat.
eGFR ‘cut-offs’ for glucose lowering therapies
Diabetes mellitus pharmacotherapy
Antihyperglycemic therapy in type 2 diabetes: general recommendations (22). Antihyperglycemic therapy in type 2 diabetes: general recommendations (22).
DM management Dr.Duaa Hiasat.
Oral hypoglycemics Jennifer R Marks, MD.
Renal licences of commonly used anti-diabetes drugs
Strategies for Choosing 2nd and 3rd Line Agents in Type 2 Diabetes
Presentation transcript:

Hyperglycemia Management – Medication Therapy Janice Frueh, PharmD, BCPS Associate Clinical Professor SIUE School of Pharmacy June 2nd , 2015

Objectives Compare and contrast differences in the physiologic effects for glucose control of newer anti-hyperglycemia medications Describe important considerations for effective and safe use of newer anti-hyperglycemia medications and medication delivery devices

Diabetes Self-Management Education and Support = The City of New York. http://www.nyc.gov/html/doh/html/hcp/diabetes-provider-kit.shtml. Accessed on May 2015

Oral & non-insulin injectable medications Class Agent(s) Available as -Glucosidase inhibitors Acarbose Miglitol Precose or generic Glyset Amylin analogue Pramlintide Symlin Biguanide Metformin Glucophage or generic Bile acid sequestrant Colesevelam WelChol DPP-4 inhibitors Alogliptin Linagliptin Saxagliptin Sitagliptin Nesina Tradjenta Onglyza Januvia Dopamine-2 agonist Bromocriptine Cycloset Glinides Nateglinide Repaglinide Starlix or generic Prandin Class Agent(s) Available as GLP-1 receptor agonists Albiglutide Dulaglutide Exenatide Exenatide XR Liraglutide Tanzeum Trulicity Byetta Bydureon Victoza SGLT2 inhibitors Canagliflozin Dapagliflozin Empagliflozin Invokana Farxiga Jardiance Sulfonylureas Glimepiride Glipizide Glyburide Amaryl or generic Glucotrol or generic Diaeta, Glynase, Micronase, or generic Thiazolidinediones Pioglitazone Rosiglitazone Actos or genetic Avandia DPP-4 = dipeptidyl peptidase; GLP-1 = glucagon-like peptide; SGLT2 = sodium glucose cotransporter 2. Garber AJ, et al. Endocr Pract. 2013;19(suppl 2):1-48. Inzucchi SE, et al. Diabetes Care. 2012;35:1364-1379..

Insulin medications and delivery devices V-Go® Insulin Delivery System Agent Available as Basal NPH Glargine U-100 Glargine U-300 Detemir Lantus (Pen = SoloSTAR) Levemir (Pen=FlexTouch) Basal-Prandial Regular U-500 Prandial Regular Humulin R Novlooin R Aspart Glulisine Lispro Novolog (Pen=FlexPen) Apidra (Pen = SoloSTAR) Humalog (Pen=KwikPen) Afrezza ® Inhaled Insulin Garber AJ, et al. Endocr Pract. 2013;19(suppl 2):1-48. Inzucchi SE, et al. Diabetes Care. 2012;35:1364-1379. Picture from Valertiras. http://www.go-vgo.com/what-is-vgo. Accessed on March 2015 Picture from Sanofi-Aventis. https://www.afrezza.com. Accessed on May 2015

Antihyperglycemic therapy in type 2 diabetes: general recommendations. Silvio E. Inzucchi et al. Type 2 DM Antihyperglycemic Therapy: General Recommendations Diabetes Care 2015;38:140-149

At 3 month f/u = 6 choices for medication management Antihyperglycemic therapy in type 2 diabetes: general recommendations. At 3 month f/u = 6 choices for medication management Silvio E. Inzucchi et al. Type 2 DM Antihyperglycemic Therapy: General Recommendations Diabetes Care 2015;38:140-149 Silvio E. Inzucchi et al. Dia Care 2015;38:140-149 ©2015 by American Diabetes Association

At 3 month f/u =LOTS of choices for medication management Antihyperglycemic therapy in type 2 diabetes: general recommendations. At 3 month f/u =LOTS of choices for medication management Silvio E. Inzucchi et al. Type 2 DM Antihyperglycemic Therapy: General Recommendations Diabetes Care 2015;38:140-149

PATIENT TAKE HOME MESSAGE: Individualized Approach to Blood Sugar Control Targets Medication management of hyperglycemia focuses on: Efficacy (how much the A1c decreases) Hypoglycemia risk (patient AND medication risk factors) Impact on weight Other side effects Cost Silvio E. Inzucchi et al. Type 2 DM Antihyperglycemic Therapy: General Recommendations Diabetes Care 2015;38:140-149

Non-insulin dependent Produce Glucose Kidney Liver Normal Glucose Levels Eliminate Glucose Non-insulin dependent Brain Neurons Insulin dependent Liver Muscle Triplitt CL, Repas T, and Alvarez C. Diabetes. In:Dipiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, eds. Pharmacotherapy, 9th ed. New York: McGraw-Hill; 2014. Accessed Online: http://accesspharmacy.mhmedical.com.libproxy.siue.edu/ May 2015.

Hyperglycemia Pathophysiology: Type 2 DM Impairments in Glucose Regulation Medications Impacting Glucose Regulation Impaired insulin secretion Deficient insulin release Decrease in beta-cell mass +/- function Sulfonylureas Insulin resistance Muscle cells have impaired intracellular regulation Liver cells are less responsive to insulin and inadequately suppress glucagon levels Metformin Thiazolidinediones Blunted incretin effect GLP-1 receptor agonists DPP-4 inhibitors DPP-4 = dipeptidyl peptidase; GLP-1 = glucagon-like peptide; Garber AJ, et al. Endocr Pract. 2013;19(suppl 2):1-48. Inzucchi SE, et al. Diabetes Care. 2012;35:1364-1379.. Triplitt CL, Repas T, and Alvarez C. Diabetes. In:Dipiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, eds. Pharmacotherapy, 9th ed. New York: McGraw-Hill; 2014. Accessed Online: http://accesspharmacy.mhmedical.com.libproxy.siue.edu/ May 2015.

Oral & non-insulin injectable medications Class Agent(s) Available as -Glucosidase inhibitors Acarbose Miglitol Precose or generic Glyset Amylin analogue Pramlintide Symlin Biguanide Metformin Glucophage or generic Bile acid sequestrant Colesevelam WelChol DPP-4 inhibitors Alogliptin Linagliptin Saxagliptin Sitagliptin Nesina Tradjenta Onglyza Januvia Dopamine-2 agonist Bromocriptine Cycloset Glinides Nateglinide Repaglinide Starlix or generic Prandin Class Agent(s) Available as GLP-1 receptor agonists Albiglutide Dulaglutide Exenatide Exenatide XR Liraglutide Tanzeum Trulicity Byetta Bydureon Victoza SGLT2 inhibitors Canagliflozin Dapagliflozin Empagliflozin Invokana Farxiga Jardiance Sulfonylureas Glimepiride Glipizide Glyburide Amaryl or generic Glucotrol or generic Diaeta, Glynase, Micronase, or generic Thiazolidinediones Pioglitazone Rosiglitazone Actos or genetic Avandia DPP-4 = dipeptidyl peptidase; GLP-1 = glucagon-like peptide; SGLT2 = sodium glucose cotransporter 2. Garber AJ, et al. Endocr Pract. 2013;19(suppl 2):1-48. Inzucchi SE, et al. Diabetes Care. 2012;35:1364-1379..

GLP-1 Agonists

Take Home Points: GLP-1 receptor agonists Efficacy: ~1% A1c reduction Impact post-prandial glucose 4 -10 weeks for maximum glucose lowering effects Impact on weight: Neutral or Loss Other Side Effects/Concerns: Thyroid carcinoma  Acute pancreatitis Gastroparesis Narrow therapeutic index medications Triplitt CL, Repas T, and Alvarez C. Diabetes. In:Dipiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, eds. Pharmacotherapy, 9th ed. New York: McGraw-Hill; 2014. Accessed Online: http://accesspharmacy.mhmedical.com.libproxy.siue.edu/ May 2015.

Take Home Points: GLP-1 receptor agonists Short-acting dosage formulations Exenatide: Take with a meal. Skip dose if usual meal missed Long-acting dosage formulations Common side effect: palpable nodule, erythema at injection site. No dependence on meals If dose is missed, take within 3 days of usual administration day . HAVE 2 ROUTINE ADHERENCE METHODS. Exenatide, Albiglutide: May need up to 30-60 minutes to prepare and administer dose. Keep instructions with medication not in use or in a safe location. Only use needles provided. Discontinue use 1 month before planning pregnancy.

DPP-4 Inhibitors

Take Home Points: DPP-4 inhibitors Efficacy: 0.7-1% A1c reduction Impact post-prandial glucose 4 weeks for maximum glucose lowering effects Impact on weight: Neutral Other Side Effects/Concerns: Acute pancreatitis Liver failure [alogliptin only] Triplitt CL, Repas T, and Alvarez C. Diabetes. In:Dipiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, eds. Pharmacotherapy, 9th ed. New York: McGraw-Hill; 2014. Accessed Online: http://accesspharmacy.mhmedical.com.libproxy.siue.edu/ May 2015.

SGLT2 Inhibitors

Take Home Points: SGLT2 Inhibitors Efficacy: 0.7-1% A1c reduction Impacts fasting glucose Impact on weight: Loss/Neutral Other Side Effects/Concerns: GFR < 30min/ml, ESRD , Dialysis [Contraindicated] GU infection Ketoacidosis Triplitt CL, Repas T, and Alvarez C. Diabetes. In:Dipiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, eds. Pharmacotherapy, 9th ed. New York: McGraw-Hill; 2014. Accessed Online: http://accesspharmacy.mhmedical.com.libproxy.siue.edu/ May 2015.

Insulin medications and delivery devices V-Go® Insulin Delivery System Agent Available as Basal NPH Glargine U-100 Glargine U-300 Detemir Lantus (Pen = Solostar) Levemir (Pen=FlexTouch) Basal-Prandial Regular U-500 ???? Prandial Regular Humulin R Novlooin R (??) Aspart Glulisine Lispro Novolog (Pen=??? Apidra (Pen=??) Humalog (Pen=??) Afrezza ® Inhaled Insulin Garber AJ, et al. Endocr Pract. 2013;19(suppl 2):1-48. Inzucchi SE, et al. Diabetes Care. 2012;35:1364-1379. Picture from Valertiras. http://www.go-vgo.com/what-is-vgo. Accessed on March 2015 Picture from Sanofi-Aventis. https://www.afrezza.com. Accessed on May 2015

Picture from Valertiras. http://www. go-vgo. com/why-v-go Picture from Valertiras. http://www.go-vgo.com/why-v-go. Accessed on May 2015

V-Go® Insulin Delivery System Simple, discrete way to administer insulin Do not have to travel with needles, pens, or vials Maintenance Dose: Reach 50/50 split on daily basal-bolus insulin dose V-GO Start Guide. http://www.go-vgo.com/sites/default/files/upload/hcp-start-guide.pdf Accessed on May 2015

V-Go® Insulin Delivery System V-GO Start Guide. http://www.go-vgo.com/sites/default/files/upload/hcp-start-guide.pdf Accessed on May 2015

Afrezza ® Inhaled Insulin Indication Age > 18 years old Type 1 or 2 DM Contraindications Chronic lung disease (asthma, COPD) Precautions (history of/at risk for) Lung cancer Diabetic ketoacidosis Hypokalemia

Afrezza ® Inhaled Insulin Efficacy: similar to prandial insulin options Impact post-prandial glucose 3-5 days for maximum glucose lowering effects Impact on weight: Weight Gain Other Side Effects/Concerns: Cough (common) Throat pain/irritation (common) Hypoglycemia (similar to prandial insulin options) Fluid retention

Questions??